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Objective. We hypothesized that HMGB1 in complex with bacterial components, such as ﬂagellin, CpG-ODN, and LPS, promotes
HIV-1 replication. Furthermore, we studied the levels of antiﬂagellin antibodies during HIV-1-infection. Methods. Chronically
HIV-1-infected U1 cells were stimulated with necrotic extract/recombinant HMGB1 in complex with TLR ligands or alone.
HIV-1 replication was estimated by p24 antigen in culture supernatants 48–72 hours after stimulation. The presence of systemic
anti-ﬂagellin IgG was determined in 51 HIV-1-infected patients and 19 controls by immunoblotting or in-house ELISA. Results.
Flagellin, LPS, and CpG-ODN induced stronger HIV-1 replication when incubated together with necrotic extract or recombinant
HMGB1 than activation by any of the compounds alone. Moreover, the stimulatory eﬀect of necrotic extract was inhibited
by depletion of HMGB1. Elevated levels of anti-ﬂagellin antibodies were present in plasma from HIV-1-infected patients and
signiﬁcantly decreased during 2 years of antiretroviral therapy. Conclusions. Our ﬁndings implicate a possible role of HGMB1-
bacterial complexes, as a consequence of microbial translocation and cell necrosis, for immune activation in HIV-1 pathogenesis.
We propose that ﬂagellin is an important microbial product, that modulates viral replication and induces adaptive immune
responses in vivo.
1.Introduction
Antiretroviral therapy (ART) suppresses eﬃciently the repli-
cation of human immunodeﬁciency virus type 1 (HIV-1) to
undetectable levels with standard techniques in most treated
patients, but there is still an ongoing low-grade replication in
most or all patients [1]. Also, immune activation is a central
feature of progressive HIV-1 infection [2–4], and although
the degree of immune activation is decreased during ART,
it is not normalized [5]. The pathogenic mechanisms for
the persistent immune activation remain further to be deter-
mined. This is especially important since studies suggest that
the remaining immune activation may cause organ damage,
forexample,anincreasedriskforcardiovasculardiseasesand
possibly neurocognitive dysfunction [5, 6].
The gastrointestinal (GI) immune system seems to play
a central role in the pathogenesis of immune activation [7].
The early dramatic depletion of CD4+ T cells from the
gut mucosa may drive immune activation, as this mucosal
immune damage impairs the normal barrier function and
allows increased translocation of bacterial products from
the gut lumen into the circulation [8]. We and others have
shown that microbial translocation is present in HIV-1
infection through increased plasma LPS levels in subjects
with progressive disease and that the levels are decreased by
ART [9–11].2 International Journal of Microbiology
Furthermore, we and others have implied that the
alarmin high-mobility group binding 1 protein (HMGB1)
modulates HIV-1 replication in vitro and contributes to
the activation of immune system [12–14]. Thus, plasma
HMGB1 levels are elevated in HIV-1-infected patients and
reducedwitheﬀectiveART[11,15].HMGB1isreleasedfrom
damagedornecroticcellstotheextracellularmilieu,inwhich
it may act as a potent proinﬂammatory marker by stimulat-
ing cytokine expression in monocytes and endothelial cells
[16, 17]. HMGB1 per se does not seem to have a pro-
inﬂammatory activity [18, 19] but has a high aﬃnity to form
complexes with other molecules such as LPS and CpG-DNA
[20]. These complexes are likely to bind to various receptors,
including TLR4 and TLR9, and promote a large variety of
inﬂammatory and immunological responses [20, 21].
The aim of our study was to explore whether complexes
ofHMGB1andTLRligands,suchasﬂagellin,couldsynergis-
tically induce HIV-1 replication in a promonocytic cell line.
2. Methods
2.1. Ethic Statement. All research involving human par-
ticipants has been conducted according to the principles
expressed in the Declaration of Helsinki. Patients gave
their informed written consent and the study protocol was
approved by the Regional Ethics Committee in Stockholm,
Sweden (Dnr 2005/3:10).
2.2. Reagents. Lipopolysaccharide (LPS) and (phorbol-12-
myristate-13-acetate) PMA were obtained from Sigma (St.
Louise, MO, USA), IL-1β from R&D Systems (Minneapolis,
MN, USA), and CpG-ODN type B (ODN2006), puriﬁed
ﬂagellin (S.typhimurium), and anti-ﬂagellin (FliC) antibod-
ies from InvivoGen (San Diego, CA, USA and Abcam,
Cambridge, UK). Recombinant HMGB1 (HM-116) was
purchased from HMGBiotech (Milan, Italy) or from R&D
systems(Minneapolis,MN,USA).Wealsousedrecombinant
HMGB1 [19] that was a kind gift from Professor Helena
Erlandsson-Harris CMM/KI, Stockholm.
2.3. Cell Cultures. U1 cells, a subclone derived from U937
cells, were obtained through the AIDS Research and Ref-
erence Reagent Program (NIAID, NIH). The U1 cells are
chronically infected with HIV-1 and are characterized by low
constitutivelevelsofvirusexpressionthatcanbeupregulated
by several cytokines and phorbol esters. The cells were main-
tained in RPMI medium (Gibco) supplemented with 10%
fetalcalfserum,glutamine,andantibiotics.Cellswereseeded
at 200 000cells/mL in 96-well plates and complexes/TLR-
ligands/controls were added and incubated for 48 or 72
hours.
2.4. Patients. Patients (n = 51) given ART, followed at the
Department of Infectious Diseases, Karolinska University
Hospital, Stockholm, and 19 healthy controls were included.
Patients’ recruitment was based on sample availability as
well as virologic response after 2 years of ART. Thirty-three
individualshadundetectableviralloadand18haddetectable
viraemia (nonresponders) after 2 years of treatment. This
cohort(42of51patients)hasbeendescribedpreviously[11].
The age and sex distribution of the patients and controls was
similar (median age 38 years, 52% women).
2.5. Preparation of Necrotic Cell Extracts. Necrotic extracts
were obtained as previously described [22]. Brieﬂy, necrosis
wasinducedinperipheralbloodmononuclearcells(PBMCs)
fromhealthydonors(30 ×106 cells/mL)byexposingthecells
tosixcyclesoffreezingandthawing.Celldebriswasremoved
by centrifugation and the supernatant was passed through
a0 . 2 μm membrane and collected. The concentration of
HMGB1 in necrotic extracts was 40μg/mL, as estimated
by immunoblot (data not shown). Furthermore, 250μLo f
necrotic extract was incubated with polyclonal anti-HMGB-
1 antibodies (Abs) from ABCAM (Cambridge, UK). Samples
were incubated at 4◦C for 16 hours. As control, nonspeciﬁc
Abs(RabbitpolyclonalIgG)wasutilized.Immunecomplexes
were removed by adding 25μL of Sepharose A/G to the
extract, incubated for 1.5 hours at 4◦C, and centrifuged. The
supernatant was collected and the procedure was repeated
again with 25μL sepharose for 1 hour at 4◦C.
2.6. Preparation of HMGB1 Complexes. Necrotic extract or
HMGB1was mixed with the TLR-ligands, LPS, CpG-ODN,
IL-1β, and ﬂagellin in PBS in diﬀerent concentrations and
incubated for 16 hours at 4◦C. Concentrations are given
in Figures 1–3. The suboptimal stimulatory concentrations
(capable to trigger HIV replication from U1 cells) of necrotic
extract as well as LPS, ﬂagellin, CpG-ODN, and Il-1β were
estimated in a series of experiments (data not included).
Complexes were also mixed and denatured by heating at
95◦C for ﬁve minutes to verify the stimulatory eﬀect of
complex formation on U1 cells.
2.7.CharacterizationofHMGB1withImmunoblotting. Equal
volumes of necrotic cell extracts, HMGB1-depleted necrotic
cell extracts, as well as recombinant HMGB1 proteins
were resolved on 10–20% Tris/glycine gel and transferred
onto nitrocellulose membrane (Invitrogen, Carlsbad, USA).
The membranes were then incubated overnight with anti-
HMGB1 Abs at 1:2000dilution. The following day, the
membranes were incubated 1h with horseradish-peroxidase
(HRP-) conjugated secondary antibody (GE, Healthcare),
raised against rabbit IgG at 1:10,000dilution. The proteins
were ﬁnally visualized using ECL reagents (GE, Healthcare).
2.8. Immunoblotting of Antiﬂagellin Antibodies. Approxi-
mately 1.88μg of recombinant ﬂagellin was twofold seri-
ally diluted (4 series) and subjected to gel electrophore-
sis on 10–20% precasted SDS-PAGE gel (Invitrogen) in
Tris/glycine/SDS buﬀer. Similarly, bacterial extracts of ﬂag-
ellated E. coli strain O126:H2 and aﬂagellate E. coli O21:H-
(CCUG catalog number 11425 and 11326, kind gift
from Professor Andrej Weintraub, Clinical Microbiology/KI,
Stockholm) that were prepared freshly from an overnight
inoculation werealsoresolvedonSDS-PAGEgelasdescribed
previously. The proteins were then electroblotted onto iBlotInternational Journal of Microbiology 3
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Figure 1: HMGB1 present in necrotic extract induces HIV-1 repli-
cation in U1 cells. (a) Western blot of cell supernatants (necrotic
extracts) obtained after freeze-thawing cycles of peripheral blood
mononuclear cells (PBMC) (30 × 106 cells/mL) from healthy
donors: Molecular weight marker (I); supernatants after immune
depletion of HMGB1 with nonspeciﬁc rabbit polyclonal antibody
(II); depletion with anti-HMGB1 antibody −5μg (III) and 10μg
(IV); necrotic extract loaded 20μL( V ) ,1 0μL( V I ) ,a n d5μL (VII);
100ng (VIII) and 75ng (IX) of recombinant HMGB1; cell debris
(X).Numberstotheleftdepictpositionsofmolecularmassmarkers
(in kDa). (b) Levels of HIV p24 protein in cell culture supernatants
after 72h incubation of U1 cells with necrotic extract (HMGB1
concentration 1μg/mL): HMGB1-depleted necrotic extract and
mock cells. PMA served as a positive control (20nM). The levels of
viral replication were approximately 2-fold higher after stimulation
by necrotic extract compared to the mock cells (P = 0.002). Results
from three independent experiments in duplicates are presented.
gel transfer stacks nitrocellulose membranes, using the iBlot
dry blotting system (Invitrogen), as recommended by the
manufacturer. After blocking the nitrocellulose membranes
for 1 hour in blocking buﬀer (PBS supplemented with 0.05%
Tween and containing 10% nonfat milk), the blots were
probed with primary antibodies overnight at 4◦Cw i t ha
slow agitation. As primary antibody, serum from HIV-1-
infected or control subjects diluted 1:1000, monoclonal, or
polyclonal anti-ﬂagellin Abs was used. The following day,
the membranes were washed with PBS containing 0.05%
(vol/vol) Tween and bound antibodies were then detected
by using HRP-conjugated secondary Abs (Pierce) against
human IgG in 1:10,000dilution. Protein bands were visual-
ized by chemiluminescence (Thermo Scientiﬁc). To conﬁrm
the protein bands, two immunoblotted membranes from
HIV-1-infected patients and control subjects were stripped
oﬀ and reprobed with mouse monoclonal antibody directed
against ﬂagellin. Bound antibodies were then detected by
using an HRP-conjugated secondary antibody, raised against
mouse (DAKO; 1:4.000).
2.9. Speciﬁc and Total Antibodies Measurement. Antibody
titers against ﬂagellin, measles, and total IgG levels were
assessed by ELISA. An in-house anti-ﬂagellin-speciﬁc IgG
ELISA was developed using puriﬁed ﬂagellin monomers
from S. typhimurium (InvivoGen). It has been previously
shown that human sera have a similar recognition pattern
of ﬂagellin monomers whether isolated from ﬂagellated
E. coli or S. typhimurium [23]. Brieﬂy, microwell plates
(MWP) were coated overnight with puriﬁed ﬂagellin from
S. typhimurium (25ng/well). The following day, plasma
samples from HIV-1-infected and control subjects diluted
1:1000 were applied to wells coated with ﬂagellin. After
incubation and washing, the MWPs were incubated with
HRP-conjuggated anti-human IgG. For total IgG ELISA,
the manufacturer’s procedure was followed (MABTECH,
Nacka, Sweden). The Enzygnost Measeles virus IgG ELISA
kit (Behring, Germany) was utilized for quantiﬁcation of
antimeasles antibodies.
2.10. Plasma HIV-1 RNA Quantiﬁcation and CD4+/CD8+ T-
Cell Counts. Plasma HIV-1 RNA levels (COBAS Amplicor
test Roche Molecular Systems; USA; detection limit 40
copies/mL) and T-cell counts (ﬂow cytometry) were evalu-
ated as part of clinical routine.
2.11. HIV-1 Replication Assay. Supernatants were collected
at indicated time points and tested for the presence of
HIV p24 antigen with Architect i2000 HIV-1 Ag/Ab combo
detection system (Abbott Diagnostics, Abbott Park, IL,
USA). The p24 concentration was calculated based on the
several standard dilutions of p24 protein included in each
run.
2.12. Statistics. Data are presented as median, interquartile
range, and total range. Diﬀerences between groups were
analysed with the Mann-Whitney U-test, and intragroup
changes from baseline to the end of the study were evaluated
by Wilcoxon test. Jonckheere-Terpstra test was used for trend
analyses and correlation analyses were performed using the
Spearman method. A two-tailed signiﬁcance level of 0.05
was used. The statistical analyses were performed with SPSS
software, version 15.0 (SPSS Inc, Chicago, USA).
3. Results
3.1. Necrotic Cellular Extract Upregulates HIV-1 Replication
in U1 Cells. To determine the impact of an endogenous
signal, associated with cell injury, on HIV-1 replication,
we generated soluble necrotic extracts from healthy donors
PBMCs. Western blot conﬁrmed the presence of large
amounts of HMGB1 in the extracts. Additionally HMGB1-
depleted extracts were obtained by immune depletion uti-
lizing speciﬁc anti-HMGB1 antibodies (Figure 1(a)). In the
initial experiment, the U1 cells were exposed to necrotic4 International Journal of Microbiology
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Figure 2: Necrotic extract and TLR-ligands in complexes upregulate viral replication in U1cells. U1cell cultures were stimulated with
necrotic extract (HMGB1 concentration 1μg/mL) and Toll-like receptor ligands: LPS 10ng/mL (a), CpG-ODN 1μg/mL (b), ﬂagellin
50ng/mL (c), and IL-1β 0.25ug/mL (d) alone or in complexes. Supernatants from mock cells served as controls. Supernatants were collected
from cell cultures after 72 hours. Results from three independent experiments in duplicates are presented.
extract, HMGB1-depleted extract, and PMA, respectively.
The HIV p24 antigen concentration in the cell supernatants
was measured after 72 hours (Figure 1(b)) .T h el ev e l so fvi ra l
replication were approximately 2-fold higher after stimula-
tion by necrotic extract compared to the mock cells (P =
0.002). Thestimulation withPMAgavea10-foldhigherviral
replication than stimulation with necrotic extract. Notably,
addition of necrotic extract depleted of HMGB1 did not
result in an increase of viral replication, as compared to the
controls, suggesting that HMGB1 crucially contributes to the
stimulatory eﬀect of the necrotic extract.
3.2. Interacting Eﬀect of TLR Ligands and Necrotic Extract on
HIV-1 Replication in U1 Cells. Thereafter, we stimulated the
U1 cells with necrotic extract, TLR ligands (LPS, ﬂagellin,
CpG-ODN), and IL-1β a l o n eo rw i t ht h ec o m p l e x e so f
necrotic extract and the TLR ligands or IL-1β.N o t a b l y ,
stimulation with all the TLR ligands, in combination with
necrotic extract, resulted in a higher viral replication than
stimulation with necrotic extract or TLR ligands alone
(Figure 2). Hence, stimulation with LPS, CpG-ODN and IL-
1β in complexes with necrotic extract resulted in a 1.5–2-
fold-increasedviralreplicationcomparedtoeachcomponent
alone, whereas ﬂagellin in combination with necrotic extract
resulted in a 7-fold increased replication compared to
ﬂagellin alone and a 13-fold-increased replication compared
to necrotic extract alone. The preheating of complexes prior
incubation with cells resulted in abrogation of stimulatory
signal, implying that the active compound relies on intact
protein structure (data not included).International Journal of Microbiology 5
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Figure 3: Interacting eﬀect of recombinant HMGB1 and TLR-ligand complexes in U1 cells. Inhibition of ﬂagellin complexes induced HIV-1
replication by anti-TLR5 antibodies. U1 cells were stimulated with recombinant HMGB1 (1μg/mL) and TLR ligands: LPS 10ng/mL (a),
CpG-ODN 1μg/mL (b) and ﬂagellin 10ng/mL (c) alone or in complexes. (d) U1 cells were incubated with 0.1 and 0.01ug/mL anti-TLR5
antibodies (TLR5 Ab) for 1 hour and then exposed to necrotic extract (NC) and HMGB1-depleted necrotic extract (DNC), alone or in
complexes with ﬂagellin (10ng/mL). HIV-1 replication was estimated after 48 hours of incubation. A dose-dependent inhibition of ﬂagellin-
necrotic extract complexes stimulatory eﬀect is present in wells pretreated with anti-TLR5 antibodies (P for trend < 0.001). Results from
three independent experiments in duplicates are shown.
3.3. Interacting Eﬀect of TLR Ligands and HMGB1 on HIV-
1 Replication in U1Cells. In order to explore if HMGB1
could mimic the synergistic eﬀects of necrotic extract-TLR
ligands,wechallengedtheU1cellswithcomplexesconsisting
of HMGB1 and bacterial substances. Indeed, stimulation
with microbial products (LPS, ﬂagellin, or CpG-ODN)
in combination with HMGB1 resulted in a higher viral
replication than stimulation with HMGB1 or TLR ligands
alone (Figures 3(a)–3(c)). Stimulation with LPS, ﬂagellin,
and CpG-ODN in combination with HMGB1 resulted in
a 1.5–2-fold-increased viral replication compared to each
component alone, although the stimulatory eﬀect was not as
prominent as with TLR ligands in combination with necrotic
extract.
3.4. Dose-Dependent Inhibition of Flagellin by Anti-TLR5. It
is known that immune response to ﬂagellin is mediated by
TLR5. To investigate whether anti-TLR5 antibodies could
block the inducing eﬀects of ﬂagellin, we ﬁrst preincubated
U1 cells with anti-TLR5 antibodies and subsequently added6 International Journal of Microbiology
the necrotic extract complexed with ﬂagellin. Flagellin in
combination with HMGB1-depleted extract gave a 3-fold-
increased viral replication compared to depleted extract
alone, whereas ﬂagellin in combination with necrotic extract
gave a 4-fold increase compared to necrotic extract alone
(Figure 3(d)). Preincubation of U1 cells with anti-TLR-
5 antibodies before addition of necrotic extract-ﬂagellin
complexes resulted in a dose-dependent inhibition of this
stimulatory eﬀect (P for trend < 0.001). Addition of anti-
TLR5 antibodies alone did not aﬀect viral replication.
3.5. Detection of Antiﬂagellin Antibodies in HIV-1-Infected
Patients. Encouraged by the in vitro data we aimed to eval-
uate whether ﬂagellin is a potentially important antigen in
vivo during HIV-1 infection. Therefore, serum samples from
HIV-1-infected patients and control subjects were used to
measure the level of ﬂagellin-speciﬁc antibodies by Western
blot analysis. When diluted 1:1000, all of the sera samples
from the HIV-1-infected patients analyzed exhibited easily
detectable bands that recognized the ﬁrst two dilutions of
ﬂagellin derived from S. typhimurium (Figure 4(a),u p p e r
panels). A relative increase in ﬂagellin-speciﬁc IgG in HIV
patients was observed if serum samples were diluted 1:500.
In contrast, in only one control subject (CS#2) ﬂagellin
was detected faintly at the highest dilution (Figure 4(a),
lowerpanels).Althoughsemiquantitativeanalysisofdetected
bands was not performed, the levels of ﬂagellin-speciﬁc IgG
observed were in all cases strikingly elevated in HIV-1-
infected patients. Similar pattern of anti-ﬂagellin IgG was
observed when plasma instead of sera was used. In order
to address the speciﬁcity of the ﬂagellin IgG, we subjected
the bacterial lysates from ﬂagellated and aﬂagellate E. coli
to protein separation on the SDS-PAGE gel. The Western
blotting with HIV-1 serum (as a primary antibody) showed
similarpatternaswhenthepolyclonalanti-ﬂagellinantibody
wasusedconﬁrmingthatthespeciﬁcityoftheantibodieswas
not limited to the recombinant protein (Figure 4(b)).
Furthermore,weusedtheanti-ﬂagellinELISAtoevaluate
the levels of ﬂagellin IgG in plasma of HIV-1-infected
patients before and after two years of ART. At baseline
signiﬁcantly elevated levels of ﬂagellin antibodies were
found in HIV-1-infected patients as compared to controls
(P<0.001) (Figure 5(a)). This diﬀerence persisted (P<
0.001) when the ﬂagellin antibodies were adjusted to the
total IgG (Figure 5(b)), suggesting that the elevation of
ﬂagellin antibodies was not due to hypergammaglobu-
linemia. Moreover, analysis of antimeasles antibodies in
10 patients with severe immune deﬁciency (CD4+ T-
cell counts ≤ 200) supported that the elevation of the
ﬂagellin antibodies was not caused by polyclonal activa-
tion Supplementary Table 1 (see supplementary material
available online at doi:10.1155/2012/263836). The levels of
ﬂagellin IgG, total IgG, and the ratio ﬂagellin IgG/total
IgG were signiﬁcantly reduced after two years of ART for
the whole group (P<0.001, P = 0.03, and P<
0.001, resp. Figures 5(a)–5(c)). Additionally a signiﬁcant
reduction of ﬂagellin IgG levels was observed also when the
patients were subdivided into those with successful ART and
the nonresponders who had remaining low levels of viral
replication two years after initiating the ART (P = 0.009;
P = 0.001, resp.). The total IgG levels after ART did
not decrease in nonresponders as they did in successfully
treated patients (P<0.001) (data not shown).
We found no correlation between the levels of ﬂagellin
IgG and the viral load nor the CD4/CD8 T-cell counts. In
contrast, among the subgroup of 42 patients in whom we
had earlier analysed HGMB1 and LPS in plasma, signiﬁcant
correlations were found between the levels of ﬂagellin IgG
and LPS (r = 0.32; P = 0.02) as well as between the ﬂagellin
IgG/total IgG ratio and LPS (r = 0.25; P = 0.007) (data not
shown).
4. Discussion
Microbial translocation has been described in diﬀerent
conditions like inﬂammatory bowel disease, neutropenia,
and chronic viral infections [6, 24]. In HIV-1 infection, the
proof for the translocation of bacterial products is based
mainly on LPS data [9, 11, 25, 26]. However, the original
observation that increased LPS levels were associated with
both activated memory CD8+ T cells and enhanced IFN-α
levels implies the involvement of other factors [9].
We therefore hypothesized that HMGB1 could be such a
link between the microbial products and hyperinﬂammation
[27]. Mounting evidence shows that HMGB1 does not act
alone but forms stable potent proinﬂammatory complexes
with other molecules, such as bacterial products or single
stranded DNA [18–20, 28]. Since we have earlier shown
that HMGB1 alone activates latent HIV-1 replication in vitro
[12], we decided to expand our analysis to the eﬀect of
HGMB1 in complexes with bacterial products. Here, we
present that HMGB1 in complex with the TLR ligands (LPS,
CpG-ODN, ﬂagellin) and IL-1β induce viral replication in a
promonocytic cell line, U1 cells. The data obtained with
both the HMGB1 derived from necrotic extract as well as
recombinant protein yielded similar results, although the
stimulatory signals associated with necrotic HMGB1 were
more potent. This is not surprising as other endogenous
danger signals should be anticipated in this process [20]. The
reduction of the stimulatory eﬀect by depletion of HGMB1
also supports our hypothesis that HMGB1 is an important
component of these complexes.
These in vitro ﬁndings brought our attention to ﬂagellin
as a potent activator of HIV-1 replication alone or in
complexeswithHMGB1.Bacterialﬂagellinsarepresentinall
motile bacteria and play an important role in mediating gut
inﬂammation associated with infection by enteric pathogens
or in inﬂammatory bowel diseases [29]. Their proinﬂam-
matory activity is exerted mainly through TLR5 [30, 31]. It
has been recently demonstrated that ﬂagellin is the major
antigen activating innate and adaptive immune response in
intestinal inﬂammation observed in Crohn’s disease [32, 33].
Disruptionoftheintestinalbarrierpromotestranslocationof
ﬂagellated commensal bacteria across the epithelium driving
the activation of innate immune cells residing in the lamina
propria.ThisphenomenonresultsalsoinabnormalexposureInternational Journal of Microbiology 7
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Figure 4: HIV-1-infected patients exhibit elevated levels of ﬂagellin-speciﬁc antibodies. (a) Approximately 1.8μg of recombinant ﬂagellin
was twofold serially diluted (4 series) and resolved on 10–20% SDS-PAGE gel, transferred onto a nitrocellulose membrane, and detected
with immunoblot assay. Serum from HIV-1-infected or control subjects diluted 1:1000 was used as a primary antibody. Each panel is
a separate immunoblot of the same recombinant ﬂagellin detected with serum from HIV-1 patients (HIV 1, HIV 2, HIV 3, HIV 4) or
control subjects (CS 1, CS 2). To conﬁrm equal sample loading and protein transfer, immunoblotted membranes from HIV 1 and CS 2 were
stripped oﬀ and reprobed with monoclonal antibody directed against ﬂagellin (blots in the lower panel). The experiments were performed
using sera from ten HIV-1-infected patients and four control subjects. These presented data are representative for all immunoblots. The
position of recombinant ﬂagellin protein is indicated with an arrow to the right. Numbers to the left depict positions of molecular mass
markers (in kDa). (b) Recombinant ﬂagellin (column 1) and lysates of ﬂagellated or aﬂagellate E. coli (columns 3 and 4) were subjected to
SDS-PAGE and immunoblotted using serum from HIV infected patient (column 1 and 3, diluted 1:1000) as primary antibody or polyclonal
anti-ﬂagellin antibody (columns 2 and 4, diluted 1:1000). The membrane in column 1 was stripped oﬀ and reprobed with polyclonal anti-
ﬂagellin antibody (column 2). The numbers above the ﬁgures indicate the amount of sample loaded in each well (in μL). MM, magic marker
(Invitrogen); F+: ﬂagellated; F−: aﬂagellate whole bacterial lysate; Pkl: polyclonal; Ab: antibody. Numbers to the left depict positions of
molecular mass markers (in kDa).8 International Journal of Microbiology
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Figure 5: Elevated levels of anti-ﬂagellin IgG are reduced during ART. Plasma levels (OD) of anti-ﬂagellin IgG (a), ratio anti-ﬂagellin
IgG/totalIgG(b),andtotalIgG(c)inhealthycontrols,HIV-1-infectedindividualsbefore(=na¨ ıve)andaftertwoyearsofART(antiretroviral
therapy). The plasma samples were diluted 1:1000. The data are presented as median 25–75 interquartile range and total range. P values refer
to intergroup diﬀerences.
of immune cells to ﬂagellin, a process that may inﬂuence the
balance and function of the diﬀerent T-cell subsets present
in the gut-associated immune system (GALT) and promote
inﬂammation [29, 34].
The contribution of ﬂagellin to immune activation
duringHIV-1infectionhasbeenanticipated[7],butthedata
are scarce. Thus, exposure of PBMCs to ﬂagellin resulted in
activation of T cells predominantly of central memory and
eﬀector memory phenotype [35]. Moreover, ﬂagellin is able
to induce HIV-1 gene expression in resting memory CD4+ T
cells that are considered as a key cellular HIV-1 reservoir in
infected individuals [36].
Our in vitro and in vivo ﬁndings are clearly in line with
the hypothesis of an important role of ﬂagellin in HIV-1
pathogenesis. Thus, we demonstrated that ﬂagellin com-
plexes are able to signiﬁcantly stimulate the HIV-1 replica-
tion, at least from cells of monocytic origin. Furthermore,
our ﬁnding that elevated levels of anti-ﬂagellin IgG are
present in HIV-1-infected individuals anticipates that this
observation has in vivo implications. Hence, we show not
only presence of elevated levels of ﬂagellin antibodies before
the initiation of ART but also a reduction after two years of
ART suggesting decreased exposure to the antigen probably
due to partial restoration of gut-blood barrier [25, 37].International Journal of Microbiology 9
The hypergammaglobulinemia present during the HIV-1
infection cannot be solely responsible for the elevation of
ﬂagellin IgG levels as the normalisation to the IgG did not
inﬂuence the results.
An elevated adaptive immune response to ﬂagellin has
been previously observed in conditions associated with gut
barrier dysfunction such as Crohn’s disease and short bowel
syndrome [23, 24] and relates to the severity of Crohn’s
disease [38]. Also, Kamat et al. [39] reported recently the
presence of a subgroup of anti-ﬂagellin antibodies (anti-
CBir1) in 4/26 HIV-1-infected patients with CD4+ T-cells
counts <300 cells/ul and high LPS levels. The CBir1 ﬂagellin
has been identiﬁed as an immune dominant ﬂagellin in
Crohn’s disease and linked to Clostridia species. Interestingly
a recently presented work has shown alterations in bacterial
composition of microbiota during HIV-1 infection with
signiﬁcantly lower ratio of Clostridia taxa in faeces obtained
from HIV-1-infected patients as compared to controls [40].
Although our assay is based on the recognition of Salmonella
typhimurium ﬂagellin which spans the two well conserved
N- and C-terminal domains of ﬂagellin [41] enabling us the
detection of broader range of ﬂagellin antibodies, additional
studies are needed to determine the antibody speciﬁcity.
Furthermore, our results deserve future studies of adaptive
ﬂagellin immune response in a larger cohort of HIV-1-
infected individuals.
In summary, the novelty of our ﬁndings is that the
bacterialproductsandHMGB1formactivecomplexeswhich
can eﬃciently not only create a proinﬂammatory milieu but
also directly trigger viral replication in infected cells. This
synergistic eﬀect may require lower levels of the interacting
substanceswhenpresentincomplexes,assuggestedbyothers
[19]. We also report that ﬂagellin has to be considered as
a microbial product that can contribute to the immune
activation during the HIV-1 infection. The formation of
HMGB1/TLR ligand complexes has direct implications on
immuneactivation,particularlyinlatestageofdisease,where
cell destruction and necrosis are dominant phenomena due
to CD4+ T-cell loss, opportunistic infections, and other
pathological conditions [27].
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